Neuroprotective Effects and Therapeutic Potential of Dichloroacetate: Targeting Metabolic Disorders in Nervous System Diseases

References

• Tovar-y-Romo LB, Penagos-Puig A, Ramirez-Jarquin JO. Endogenous recovery after brain damage: molecular mechanisms that balance neuronal life/death fate. J Neurochem. 2016;136(1):13–27. doi:10.1111/jnc.13362
   PubMed Web of Science ®Google Scholar
• Campos AC, Fogaca MV, Sonego AB, Guimaraes FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016;112:119–127. doi:10.1016/j.phrs.2016.01.033
   PubMed Web of Science ®Google Scholar
• Perez-Olives C, Rivas-Santisteban R, Lillo J, Navarro G, Franco R. Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer’s, Parkinson’s, and Huntington’s Diseases. Adv Exp Med Biol. 2021;1264:81–92.
   PubMed Web of Science ®Google Scholar
• Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14(6):615–624. doi:10.1016/S1474-4422(15)00042-3
   PubMed Web of Science ®Google Scholar
• Zhu T, Wang L, Wang LP, Wan Q. Therapeutic targets of neuroprotection and neurorestoration in ischemic stroke: applications for natural compounds from medicinal herbs. Biomed Pharmacother. 2022;148:112719. doi:10.1016/j.biopha.2022.112719
   PubMed Web of Science ®Google Scholar
• Tao T, Liu M, Chen M, et al. Natural medicine in neuroprotection for ischemic stroke: challenges and prospective. Pharmacol Ther. 2020;216:107695. doi:10.1016/j.pharmthera.2020.107695
   PubMed Web of Science ®Google Scholar
• Carrera I, Cacabelos R. Current drugs and potential future neuroprotective compounds for Parkinson’s disease. Curr Neuropharmacol. 2019;17(3):295–306. doi:10.2174/1570159X17666181127125704
   PubMed Web of Science ®Google Scholar
• Pottoo FH, Salahuddin M, Khan FA, et al. Combinatorial Regimen of Carbamazepine and Imipramine Exhibits Synergism against Grandmal Epilepsy in Rats: Inhibition of Pro-Inflammatory Cytokines and PI3K/Akt/mTOR Signaling Pathway. Pharmaceuticals (Basel). 2021;14(11):1204. doi:10.3390/ph14111204
   PubMedGoogle Scholar
• Stacpoole PW. The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?. Environ Health Perspect. 2011;119(2):155–158. doi:10.1289/ehp.1002554
   PubMed Web of Science ®Google Scholar
• James MO, Jahn SC, Zhong G, Smeltz MG, Hu Z, Stacpoole PW. Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1. Pharmacology & Therapeutics (Oxford). 2017;170:166–180. doi:10.1016/j.pharmthera.2016.10.018
   PubMed Web of Science ®Google Scholar
• Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J. 1998;329 (Pt 1)(1):191–196. doi:10.1042/bj3290191
   PubMedGoogle Scholar
• Anwar S, Shamsi A, Mohammad T, Islam A, Hassan MI. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188568. doi:10.1016/j.bbcan.2021.188568
   PubMed Web of Science ®Google Scholar
• Gray LR, Tompkins SC, Taylor EB. Regulation of pyruvate metabolism and human disease. Cell Mol Life Sci. 2014;71(14):2577–2604. doi:10.1007/s00018-013-1539-2
   PubMed Web of Science ®Google Scholar
• Abemayor E, Kovachich GB, Haugaard N. Effects of dichloroacetate on brain pyruvate dehydrogenase. J Neurochem. 1984;42(1):38–42. doi:10.1111/j.1471-4159.1984.tb09694.x
   PubMed Web of Science ®Google Scholar
• Kankotia S, Stacpoole PW. Dichloroacetate and cancer: new home for an orphan drug?. Biochim Biophys Acta. 2014;1846(2):617–629. doi:10.1016/j.bbcan.2014.08.005
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99(7):989–994. doi:10.1038/sj.bjc.6604554
   PubMed Web of Science ®Google Scholar
• Powell SF, Mazurczak M, Dib EG, et al. Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma. Invest New Drugs. 2022;40(3):622–633. doi:10.1007/s10637-022-01235-5
   PubMed Web of Science ®Google Scholar
• Tataranni T, Piccoli C. Dichloroacetate (DCA) and cancer: an overview towards clinical applications. Oxid Med Cell Longev. 2019;2019:8201079. doi:10.1155/2019/8201079
   PubMed Web of Science ®Google Scholar
• Jin J, Yuan P, Yu W, et al. Mitochondria-targeting polymer micelle of Dichloroacetate induced pyroptosis to enhance osteosarcoma immunotherapy. ACS Nano. 2022;16(7):10327–10340. doi:10.1021/acsnano.2c00192
   PubMedGoogle Scholar
• Shen H, Yu M, Tsoli M, et al. Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas. Neuro Oncol. 2020;22(1):139–151. doi:10.1093/neuonc/noz140
   PubMed Web of Science ®Google Scholar
• Sun H, Zhu A, Zhou X, Wang F. Suppression of pyruvate dehydrogenase kinase-2 re-sensitizes paclitaxel-resistant human lung cancer cells to paclitaxel. Oncotarget. 2017;8(32):52642–52650. doi:10.18632/oncotarget.16991
   PubMedGoogle Scholar
• Lu X, Zhou D, Hou B, et al. Dichloroacetate enhances the antitumor efficacy of chemotherapeutic agents via inhibiting autophagy in non-small-cell lung cancer. Cancer Manag Res. 2018;10:1231–1241. doi:10.2147/CMAR.S156530
   PubMed Web of Science ®Google Scholar
• Mangal N, James MO, Stacpoole PW, Schmidt S. Model Informed Dose Optimization of Dichloroacetate for the Treatment of Congenital Lactic Acidosis in Children. J Clin Pharmacol. 2018;58(2):212–220. doi:10.1002/jcph.1009
   PubMed Web of Science ®Google Scholar
• Mainali R, Zabalawi M, Long D, et al. Dichloroacetate reverses sepsis-induced hepatic metabolic dysfunction. Elife. 2021;10:e64611.
   PubMed Web of Science ®Google Scholar
• Li X, Liu J, Hu H, et al. Dichloroacetate ameliorates cardiac dysfunction caused by ischemic insults through AMPK signal pathway-not only shifts metabolism. Toxicol Sci. 2019;167(2):604–617. doi:10.1093/toxsci/kfy272
   PubMed Web of Science ®Google Scholar
• Tian L, Wu D, Dasgupta A, et al. Epigenetic metabolic reprogramming of right ventricular fibroblasts in pulmonary arterial hypertension: a pyruvate dehydrogenase kinase-dependent shift in mitochondrial metabolism promotes right ventricular fibrosis. Circ Res. 2020;126(12):1723–1745. doi:10.1161/CIRCRESAHA.120.316443
   PubMed Web of Science ®Google Scholar
• Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev. 2000;80(1):315–360. doi:10.1152/physrev.2000.80.1.315
   PubMed Web of Science ®Google Scholar
• Engl E, Attwell D. Non-signalling energy use in the brain. J Physiol. 2015;593(16):3417–3429. doi:10.1113/jphysiol.2014.282517
   PubMed Web of Science ®Google Scholar
• Collier JJ, Olahova M, McWilliams TG, Taylor RW. Mitochondrial signalling and homeostasis: from cell biology to neurological disease. Trends Neurosci. 2023;46(2):137–152. doi:10.1016/j.tins.2022.12.001
   PubMed Web of Science ®Google Scholar
• Garabadu D, Agrawal N, Sharma A, Sharma S. Mitochondrial metabolism: a common link between neuroinflammation and neurodegeneration. Behav Pharmacol. 2019;30(8):642–652. doi:10.1097/FBP.0000000000000505
   PubMed Web of Science ®Google Scholar
• Tian H, Chen X, Liao J, et al. Mitochondrial quality control in stroke: from the mechanisms to therapeutic potentials. J Cell Mol Med. 2022;26(4):1000–1012. doi:10.1111/jcmm.17189
   PubMed Web of Science ®Google Scholar
• Chang LH, Shimizu H, Abiko H, et al. Effect of dichloroacetate on recovery of brain lactate, phosphorus energy metabolites, and glutamate during reperfusion after complete cerebral ischemia in rats. J Cereb Blood Flow Metab. 1992;12(6):1030–1038. doi:10.1038/jcbfm.1992.140
   PubMed Web of Science ®Google Scholar
• Katayama Y, Welsh FA. Effect of dichloroacetate on regional energy metabolites and pyruvate dehydrogenase activity during ischemia and reperfusion in gerbil brain. J Neurochem. 1989;52(6):1817–1822. doi:10.1111/j.1471-4159.1989.tb07262.x
   PubMed Web of Science ®Google Scholar
• Peng J, Huang H, Wang F. 二氯醋酸钠对缺血再灌注大鼠脑保护作用的观察 [The protective effects of dichloroacetate on cerebral ischemia after reperfusion of fed rats]. Zhonghua Yi Xue Za Zhi. 1996;76(7):509–511. Chinese.
   PubMedGoogle Scholar
• Hu CL. Treatment of experimental ischemic cerebral lactic acidosis in rats with dichloroacetate. Chin J Neurol Psychiatry. 1992;25(6):355.
   Google Scholar
• Peeling J, Sutherland G, Brown RA, Curry S. Protective effect of dichloroacetate in a rat model of forebrain ischemia. Neurosci Lett. 1996;208(1):21–24. doi:10.1016/0304-3940(96)12542-8
   PubMed Web of Science ®Google Scholar
• Zhao X, Li S, Mo Y, et al. DCA Protects against Oxidation Injury Attributed to Cerebral Ischemia-Reperfusion by Regulating Glycolysis through PDK2-PDH-Nrf2 Axis. Oxid Med Cell Longev. 2021;2021:5173035. doi:10.1155/2021/5173035
   PubMed Web of Science ®Google Scholar
• Hong DK, Kho AR, Choi BY, et al. Combined treatment with Dichloroacetic acid and pyruvate reduces hippocampal neuronal death after transient cerebral ischemia. Front Neurol. 2018;9:137.
   PubMed Web of Science ®Google Scholar
• Sun Y, Li T, Xie C, et al. Dichloroacetate treatment improves mitochondrial metabolism and reduces brain injury in neonatal mice. Oncotarget. 2016;7(22):31708–31722. doi:10.18632/oncotarget.9150
   PubMedGoogle Scholar
• Guan X, Wei D, Liang Z, et al. FDCA Attenuates Neuroinflammation and Brain Injury after Cerebral Ischemic Stroke. ACS Chem Neurosci. 2023;14(20):3839–3854. doi:10.1021/acschemneuro.3c00456
   PubMed Web of Science ®Google Scholar
• Gao X, Gao YY, Yan HY, et al. PDK4 decrease neuronal apoptosis via inhibiting ROS-ASK1/P38 pathway in early brain injury after subarachnoid hemorrhage. Antioxid Redox Signal. 2022;36(7–9):505–524. doi:10.1089/ars.2021.0083
   PubMed Web of Science ®Google Scholar
• Zhao H, Mao J, Yuan Y, et al. Sodium Dichloroacetate stimulates angiogenesis by improving endothelial precursor cell function in an AKT/GSK-3beta/Nrf2 dependent pathway in vascular dementia rats. Front Pharmacol. 2019;10:523. doi:10.3389/fphar.2019.00523
   PubMed Web of Science ®Google Scholar
• Kho AR, Choi BY, Lee SH, et al. The Effects of Sodium Dichloroacetate on Mitochondrial Dysfunction and Neuronal Death Following Hypoglycemia-Induced Injury. Cells. 2019;8(5):405. doi:10.3390/cells8050405
   PubMed Web of Science ®Google Scholar
• DeVience SJ, Lu X, Proctor JL, et al. Enhancing Metabolic Imaging of Energy Metabolism in Traumatic Brain Injury Using Hyperpolarized [1-(13)C]Pyruvate and Dichloroacetate. Metabolites. 2021;11(6):335. doi:10.3390/metabo11060335
   PubMed Web of Science ®Google Scholar
• Durie D, McDonald TS, Borges K. The effect of dichloroacetate in mouse models of epilepsy. Epilepsy Res. 2018;145:77–81. doi:10.1016/j.eplepsyres.2018.06.004
   PubMed Web of Science ®Google Scholar
• Lee SH, Choi BY, Kho AR, et al. Combined treatment of dichloroacetic acid and pyruvate increased neuronal survival after seizure. Nutrients. 2022;14(22):4804. doi:10.3390/nu14224804
   PubMed Web of Science ®Google Scholar
• Miquel E, Cassina A, Martinez-Palma L, et al. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PLoS One. 2012;7(4):e34776. doi:10.1371/journal.pone.0034776
   PubMed Web of Science ®Google Scholar
• Martinez-Palma L, Miquel E, Lagos-Rodriguez V, Barbeito L, Cassina A, Cassina P. Mitochondrial Modulation by Dichloroacetate Reduces Toxicity of Aberrant Glial Cells and Gliosis in the SOD1G93A Rat Model of Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2019;16(1):203–215. doi:10.1007/s13311-018-0659-7
   PubMed Web of Science ®Google Scholar
• Palamiuc L, Schlagowski A, Ngo ST, et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol Med. 2015;7(5):526–546. doi:10.15252/emmm.201404433
   PubMed Web of Science ®Google Scholar
• Parkin ET, Hammond JE, Owens L, Hodges MD. The orphan drug dichloroacetate reduces amyloid beta-peptide production whilst promoting non-amyloidogenic proteolysis of the amyloid precursor protein. PLoS One. 2022;17(1):e0255715. doi:10.1371/journal.pone.0255715
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Ferrante RJ, Huang HM, et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington’s disease. Ann Neurol. 2001;50(1):112–117. doi:10.1002/ana.1085
   PubMed Web of Science ®Google Scholar
• O’Hara D, Davis GM, Adlesic NA, Hayes JM, Davey GP. Dichloroacetate Stabilizes Mitochondrial Fusion Dynamics in Models of Neurodegeneration. Front Mol Neurosci. 2019;12:219. doi:10.3389/fnmol.2019.00219
   PubMed Web of Science ®Google Scholar
• Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat Med. 2011;17(11):1391–1401. doi:10.1038/nm.2507
   PubMed Web of Science ®Google Scholar
• Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol. 2012;298:229–317. doi:10.1016/B978-0-12-394309-5.00006-7
   PubMed Web of Science ®Google Scholar
• Pradeep H, Diya JB, Shashikumar S, Rajanikant GK. Oxidative stress--assassin behind the ischemic stroke. Folia Neuropathol. 2012;50(3):219–230. doi:10.5114/fn.2012.30522
   PubMed Web of Science ®Google Scholar
• Bramlett HM, Dietrich WD. Pathophysiology of cerebral ischemia and brain trauma: Similarities and differences. J Cereb Blood Flow Metab. 2004;24(2):133–150. doi:10.1097/01.WCB.0000111614.19196.04
   PubMed Web of Science ®Google Scholar
• Martin E, Rosenthal RE, Fiskum G. Pyruvate dehydrogenase complex: metabolic link to ischemic brain injury and target of oxidative stress. J Neurosci Res. 2005;79(1–2):240–247. doi:10.1002/jnr.20293
   PubMed Web of Science ®Google Scholar
• Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive oxygen species in metabolic and inflammatory signaling. Circ Res. 2018;122(6):877–902. doi:10.1161/CIRCRESAHA.117.311401
   PubMed Web of Science ®Google Scholar
• Zucker SN, Fink EE, Bagati A, et al. Nrf2 amplifies oxidative stress via induction of Klf9. Mol Cell. 2014;53(6):916–928. doi:10.1016/j.molcel.2014.01.033
   PubMed Web of Science ®Google Scholar
• Chhunchha B, Kubo E, Singh DP. Sulforaphane-Induced Klf9/Prdx6 Axis Acts as a Molecular Switch to Control Redox Signaling and Determines Fate of Cells. Cells. 2019;8(10):1159. doi:10.3390/cells8101159
   PubMed Web of Science ®Google Scholar
• Cahill J, Zhang JH. Subarachnoid hemorrhage: is it time for a new direction?. Stroke. 2009;40(3 Suppl):S86–S87. doi:10.1161/STROKEAHA.108.533315
   PubMed Web of Science ®Google Scholar
• Lilla N, Fullgraf H, Stetter C, Kohler S, Ernestus RI, Westermaier T. First Description of Reduced Pyruvate Dehydrogenase Enzyme Activity Following Subarachnoid Hemorrhage (SAH). Front Neurosci. 2017;11:37. doi:10.3389/fnins.2017.00037
   PubMed Web of Science ®Google Scholar
• Westermaier T, Jauss A, Eriskat J, Kunze E, Roosen K. Time-course of cerebral perfusion and tissue oxygenation in the first 6 h after experimental subarachnoid hemorrhage in rats. J Cereb Blood Flow Metab. 2009;29(4):771–779. doi:10.1038/jcbfm.2008.169
   PubMed Web of Science ®Google Scholar
• Chen Y, Galea I, Macdonald RL, Wong G, Zhang JH. Rethinking the initial changes in subarachnoid haemorrhage: Focusing on real-time metabolism during early brain injury. EBioMedicine. 2022;83:104223. doi:10.1016/j.ebiom.2022.104223
   PubMed Web of Science ®Google Scholar
• Stockwin LH, Yu SX, Borgel S, et al. Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. Int J Cancer. 2010;127(11):2510–2519. doi:10.1002/ijc.25499
   PubMed Web of Science ®Google Scholar
• Adam-Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal. 2005;7(9–10):1140–1149. doi:10.1089/ars.2005.7.1140
   PubMed Web of Science ®Google Scholar
• Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177–185. doi:10.1016/j.cmet.2006.02.002
   PubMed Web of Science ®Google Scholar
• Chouchani ET, Pell VR, James AM, et al. A unifying mechanism for mitochondrial superoxide production during ischemia-reperfusion injury. Cell Metab. 2016;23(2):254–263.
   PubMed Web of Science ®Google Scholar
• Serrander L, Cartier L, Bedard K, et al. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J. 2007;406(1):105–114. doi:10.1042/BJ20061903
   PubMedGoogle Scholar
• Bugger H, Pfeil K. Mitochondrial ROS in myocardial ischemia reperfusion and remodeling. Biochim Biophys Acta Mol Basis Dis. 2020;1866(7):165768. doi:10.1016/j.bbadis.2020.165768
   PubMed Web of Science ®Google Scholar
• Kinugasa Y, Ogino K, Furuse Y, et al. Allopurinol improves cardiac dysfunction after ischemia-reperfusion via reduction of oxidative stress in isolated perfused rat hearts. Circ J. 2003;67(9):781–787. doi:10.1253/circj.67.781
   PubMed Web of Science ®Google Scholar
• Ricci L, Stanley FU, Eberhart T, Mainini F, Sumpton D, Cardaci S. Pyruvate transamination and NAD biosynthesis enable proliferation of succinate dehydrogenase-deficient cells by supporting aerobic glycolysis. Cell Death Dis. 2023;14(7):403. doi:10.1038/s41419-023-05927-5
   PubMed Web of Science ®Google Scholar
• Chouchani ET, Pell VR, Gaude E, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515(7527):431–435.
   PubMed Web of Science ®Google Scholar
• Oh CJ, Ha CM, Choi YK, et al. Pyruvate dehydrogenase kinase 4 deficiency attenuates cisplatin-induced acute kidney injury. Kidney Int. 2017;91(4):880–895. doi:10.1016/j.kint.2016.10.011
   PubMed Web of Science ®Google Scholar
• Brand MD. Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. Free Radic Biol Med. 2016;100:14–31. doi:10.1016/j.freeradbiomed.2016.04.001
   PubMed Web of Science ®Google Scholar
• Lin G, Hill DK, Andrejeva G, et al. Dichloroacetate induces autophagy in colorectal cancer cells and tumours. Br J Cancer. 2014;111(2):375–385. doi:10.1038/bjc.2014.281
   PubMed Web of Science ®Google Scholar
• Fisher M, Savitz SI. Pharmacological brain cytoprotection in acute ischaemic stroke - renewed hope in the reperfusion era. Nat Rev Neurol. 2022;18(4):193–202. doi:10.1038/s41582-021-00605-6
   PubMed Web of Science ®Google Scholar
• Mei ZG, Huang YG, Feng ZT, et al. Electroacupuncture ameliorates cerebral ischemia/reperfusion injury by suppressing autophagy via the SIRT1-FOXO1 signaling pathway. Aging (Albany NY). 2020;12(13):13187–13205. doi:10.18632/aging.103420
   PubMedGoogle Scholar
• Wang P, Shao BZ, Deng Z, Chen S, Yue Z, Miao CY. Autophagy in ischemic stroke. Prog Neurobiol. 2018;163–164:98–117. doi:10.1016/j.pneurobio.2018.01.001
   PubMed Web of Science ®Google Scholar
• Mo Y, Sun YY, Liu KY. Autophagy and inflammation in ischemic stroke. Neural Regen Res. 2020;15(8):1388–1396. doi:10.4103/1673-5374.274331
   PubMed Web of Science ®Google Scholar
• Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 2015;22(3):377–388. doi:10.1038/cdd.2014.150
   PubMed Web of Science ®Google Scholar
• Zou Y, Luo X, Feng Y, et al. Luteolin prevents THP-1 macrophage pyroptosis by suppressing ROS production via Nrf2 activation. Chem Biol Interact. 2021;345:109573. doi:10.1016/j.cbi.2021.109573
   PubMed Web of Science ®Google Scholar
• Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281(5381):1309–1312. doi:10.1126/science.281.5381.1309
   PubMed Web of Science ®Google Scholar
• Kaur I, Behl T, Sachdeva M, Bungau S, Venkatachalam T. Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics. Curr Mol Pharmacol. 2021;14(6):1066–1082. doi:10.2174/1874467214666210120145537
   PubMed Web of Science ®Google Scholar
• Ding L, Li J, Li W, et al. p53- and ROS-mediated AIF pathway involved in TGEV-induced apoptosis. J Vet Med Sci. 2018;80(11):1775–1781. doi:10.1292/jvms.18-0104
   PubMed Web of Science ®Google Scholar
• Liberale L, Ministrini S, Carbone F, Camici GG, Montecucco F. Cytokines as therapeutic targets for cardio- and cerebrovascular diseases. Basic Res Cardiol. 2021;116(1):23. doi:10.1007/s00395-021-00863-x
   PubMed Web of Science ®Google Scholar
• Wang P, Chen M, Yang Z, et al. Activation of pyruvate dehydrogenase activity by dichloroacetate improves survival and neurologic outcomes after cardiac arrest in rats. Shock. 2018;49(6):704–711. doi:10.1097/SHK.0000000000000971
   PubMed Web of Science ®Google Scholar
• Kim Y, Cho AY, Kim HC, Ryu D, Jo SA, Jung YS. Effects of Natural Polyphenols on Oxidative Stress-Mediated Blood-Brain Barrier Dysfunction. Antioxidants (Basel). 2022;11(2):197.
   PubMedGoogle Scholar
• Pun PB, Lu J, Moochhala S. Involvement of ROS in BBB dysfunction. Free Radic Res. 2009;43(4):348–364. doi:10.1080/10715760902751902
   PubMed Web of Science ®Google Scholar
• Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161(3):653–660. doi:10.1083/jcb.200302070
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim YH, Koh JY. Protection by pyruvate against transient forebrain ischemia in rats. J Neurosci. 2001;21(20):RC171. doi:10.1523/JNEUROSCI.21-20-j0002.2001
   PubMed Web of Science ®Google Scholar
• Vander HM, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi:10.1126/science.1160809
   PubMed Web of Science ®Google Scholar
• Bir SC, Khan MW, Javalkar V, Toledo EG, Kelley RE. Emerging Concepts in Vascular Dementia: A Review. J Stroke Cerebrovasc Dis. 2021;30(8):105864. doi:10.1016/j.jstrokecerebrovasdis.2021.105864
   PubMed Web of Science ®Google Scholar
• Williamson K, Stringer SE, Alexander MY. Endothelial progenitor cells enter the aging arena. Front Physiol. 2012;3:30. doi:10.3389/fphys.2012.00030
   PubMed Web of Science ®Google Scholar
• Jian KT, Shi Y, Zhang Y, Mao YM, Liu JS, Xue FL. Time course effect of hypoxia on bone marrow-derived endothelial progenitor cells and their effects on left ventricular function after transplanted into acute myocardial ischemia rat. Eur Rev Med Pharmacol Sci. 2015;19(6):1043–1054.
   PubMed Web of Science ®Google Scholar
• Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162–172. doi:10.1056/NEJMra1603471
   PubMed Web of Science ®Google Scholar
• Philips T, Rothstein JD. Glial cells in amyotrophic lateral sclerosis. Exp Neurol. 2014;262 Pt B:111–120. doi:10.1016/j.expneurol.2014.05.015
   PubMed Web of Science ®Google Scholar
• Kang SH, Li Y, Fukaya M, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16(5):571–579. doi:10.1038/nn.3357
   PubMed Web of Science ®Google Scholar
• Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2019;710:132933. doi:10.1016/j.neulet.2017.06.052
   PubMed Web of Science ®Google Scholar
• Feldman EL, Goutman SA, Petri S, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400(10360):1363–1380. doi:10.1016/S0140-6736(22)01272-7
   PubMed Web of Science ®Google Scholar
• Valbuena GN, Tortarolo M, Bendotti C, Cantoni L, Keun HC. Altered Metabolic Profiles Associate with Toxicity in SOD1(G93A) Astrocyte-Neuron Co-Cultures. Sci Rep. 2017;7(1):50. doi:10.1038/s41598-017-00072-4
   PubMedGoogle Scholar
• Pehar M, Cassina P, Vargas MR, et al. Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem. 2004;89(2):464–473. doi:10.1111/j.1471-4159.2004.02357.x
   PubMed Web of Science ®Google Scholar
• Izrael M, Slutsky SG, Revel M. Rising Stars: Astrocytes as a Therapeutic Target for ALS Disease. Front Neurosci. 2020;14:824. doi:10.3389/fnins.2020.00824
   PubMed Web of Science ®Google Scholar
• Fan YY, Huo J. A1/A2 astrocytes in central nervous system injuries and diseases: Angels or devils?. Neurochem Int. 2021;148:105080. doi:10.1016/j.neuint.2021.105080
   PubMed Web of Science ®Google Scholar
• Diaz-Garcia CM, Mongeon R, Lahmann C, Koveal D, Zucker H, Yellen G. Neuronal stimulation triggers neuronal glycolysis and not lactate uptake. Cell Metab. 2017;26(2):361–374. doi:10.1016/j.cmet.2017.06.021
   PubMed Web of Science ®Google Scholar
• Jia L, Liao M, Mou A, et al. Rheb-regulated mitochondrial pyruvate metabolism of Schwann cells linked to axon stability. Dev Cell. 2021;56(21):2980–2994. doi:10.1016/j.devcel.2021.09.013
   PubMed Web of Science ®Google Scholar
• Staub F, Mackert B, Kempski O, Peters J, Baethmann A. Swelling and death of neuronal cells by lactic acid. J Neurol Sci. 1993;119(1):79–84. doi:10.1016/0022-510X(93)90194-4
   PubMed Web of Science ®Google Scholar
• Zimmerman MC, Oberley LW, Flanagan SW. Mutant SOD1-induced neuronal toxicity is mediated by increased mitochondrial superoxide levels. J Neurochem. 2007;102(3):609–618. doi:10.1111/j.1471-4159.2007.04502.x
   PubMed Web of Science ®Google Scholar
• Bartosz G. Peroxynitrite: mediator of the toxic action of nitric oxide. Acta Biochim Pol. 1996;43(4):645–659. doi:10.18388/abp.1996_4461
   PubMed Web of Science ®Google Scholar
• Kirkinezos IG, Bacman SR, Hernandez D, et al. Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J Neurosci. 2005;25(1):164–172. doi:10.1523/JNEUROSCI.3829-04.2005
   PubMed Web of Science ®Google Scholar
• Cassina P, Cassina A, Pehar M, et al. Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J Neurosci. 2008;28(16):4115–4122. doi:10.1523/JNEUROSCI.5308-07.2008
   PubMed Web of Science ®Google Scholar
• Delaney LM, Ho N, Morrison J, Farias NR, Mosser DD, Coomber BL. Dichloroacetate affects proliferation but not survival of human colorectal cancer cells. Apoptosis. 2015;20(1):63–74. doi:10.1007/s10495-014-1046-4
   PubMed Web of Science ®Google Scholar
• Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185(2):232–240. doi:10.1016/j.expneurol.2003.10.004
   PubMed Web of Science ®Google Scholar
• Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci. 2000;20(7):2534–2542. doi:10.1523/JNEUROSCI.20-07-02534.2000
   PubMed Web of Science ®Google Scholar
• Hegedus J, Putman CT, Tyreman N, Gordon T. Preferential motor unit loss in the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. The Journal of Physiology. 2008;586(14):3337–3351. doi:10.1113/jphysiol.2007.149286
   PubMed Web of Science ®Google Scholar
• Baker JS, McCormick MC, Robergs RA. Interaction among skeletal muscle metabolic energy systems during intense exercise. J Nutr Metab. 2010;2010:905612. doi:10.1155/2010/905612
   PubMedGoogle Scholar
• Bassel-Duby R, Olson EN. Signaling Pathways in Skeletal Muscle Remodeling. Annu Rev Biochem. 2006;75(1):19–37. doi:10.1146/annurev.biochem.75.103004.142622
   PubMedGoogle Scholar
• Malgoyre A, Chabert C, Tonini J, Koulmann N, Bigard X, Sanchez H. Alterations to mitochondrial fatty-acid use in skeletal muscle after chronic exposure to hypoxia depend on metabolic phenotype. J Appl Physiol. 2017;122(3):666–674. doi:10.1152/japplphysiol.00090.2016
   PubMed Web of Science ®Google Scholar
• Aon MA, Bhatt N, Cortassa SC. Mitochondrial and cellular mechanisms for managing lipid excess. Front Physiol. 2014;5:282. doi:10.3389/fphys.2014.00282
   PubMed Web of Science ®Google Scholar
• Furuyama T, Kitayama K, Yamashita H, Mori N. Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation. Biochem J. 2003;375(Pt 2):365–371. doi:10.1042/bj20030022
   PubMedGoogle Scholar
• Kim MJ, Sinam IS, Siddique Z, Jeon JH, Lee IK. The link between mitochondrial dysfunction and sarcopenia: an update focusing on the role of pyruvate dehydrogenase kinase 4. Diabetes Metab J. 2023;47(2):153–163. doi:10.4093/dmj.2022.0305
   PubMed Web of Science ®Google Scholar
• Dupuis L, Gonzalez DAJ, Echaniz-Laguna A, et al. Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. PLoS One. 2009;4(4):e5390. doi:10.1371/journal.pone.0005390
   PubMed Web of Science ®Google Scholar
• Massao HS, de Oliveira CC, Mendonca JR, Piltcher HE, Fernandes LC, Curi R. Palmitate acutely raises glycogen synthesis in rat soleus muscle by a mechanism that requires its metabolization (Randle cycle). FEBS Lett. 2003;541(1–3):109–114.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zheng Q, Hong Y, et al. beta(2)-Microglobulin coaggregates with Abeta and contributes to amyloid pathology and cognitive deficits in Alzheimer’s disease model mice. Nat Neurosci. 2023;26(7):1170–1184. doi:10.1038/s41593-023-01352-1
   PubMed Web of Science ®Google Scholar
• Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. Nat Neurosci. 2015;18(6):800–806. doi:10.1038/nn.4018
   PubMed Web of Science ®Google Scholar
• Hitschler L, Lang T. The transmembrane domain of the amyloid precursor protein is required for antiamyloidogenic processing by alpha-secretase ADAM10. J Biol Chem. 2022;298(6):101911. doi:10.1016/j.jbc.2022.101911
   PubMed Web of Science ®Google Scholar
• Velliquette RA, O’Connor T, Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer’s disease pathogenesis. J Neurosci. 2005;25(47):10874–10883. doi:10.1523/JNEUROSCI.2350-05.2005
   PubMed Web of Science ®Google Scholar
• O’Connor T, Sadleir KR, Maus E, et al. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron. 2008;60(6):988–1009. doi:10.1016/j.neuron.2008.10.047
   PubMed Web of Science ®Google Scholar
• Walia V, Kaushik D, Mittal V, et al. Delineation of neuroprotective effects and possible benefits of antioxidantstherapy for the treatment of Alzheimer’s diseases by targeting mitochondrial-derived reactive oxygen species: bench to bedside. Mol Neurobiol. 2022;59(1):657–680. doi:10.1007/s12035-021-02617-1
   PubMed Web of Science ®Google Scholar
• Song T, Song X, Zhu C, et al. Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer’s disease: a meta-analysis of in vivo magnetic resonance spectroscopy studies. Ageing Res Rev. 2021;72:101503. doi:10.1016/j.arr.2021.101503
   PubMed Web of Science ®Google Scholar
• Yulug B, Altay O, Li X, et al. Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Transl Neurodegener. 2023;12(1):4. doi:10.1186/s40035-023-00336-2
   PubMed Web of Science ®Google Scholar
• Sajan MP, Leitges M, Park C, et al. Control of beta-site amyloid precursor protein-cleaving Enzyme-1 expression by protein kinase C-lambda/iota and nuclear factor kappa-B. Curr Alzheimer Res. 2021;18(12):941–955. doi:10.2174/1567205019666211222120448
   PubMed Web of Science ®Google Scholar
• Bahn G, Park JS, Yun UJ, et al. NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer’s models. Proc Natl Acad Sci U S A. 2019;116(25):12516–12523. doi:10.1073/pnas.1819541116
   PubMed Web of Science ®Google Scholar
• Ho CL, Kao NJ, Lin CI, Cross TL, Lin SH. Quercetin Increases Mitochondrial Biogenesis and Reduces Free Radicals in Neuronal SH-SY5Y Cells. Nutrients. 2022;14(16):3310. doi:10.3390/nu14163310
   PubMed Web of Science ®Google Scholar
• Zhao H, Sun M, Zhang Y, et al. Connecting the dots: the cerebral lymphatic system as a bridge between the central nervous system and peripheral system in health and disease. Aging Dis. 2023. doi:10.14336/AD.2023.05162023
   Web of Science ®Google Scholar
• Perez OJ, Swerdlow RH. Mitochondrial dysfunction in Alzheimer’s disease: role in pathogenesis and novel therapeutic opportunities. Br J Pharmacol. 2019;176(18):3489–3507. doi:10.1111/bph.14585
   PubMed Web of Science ®Google Scholar
• Borsche M, Pereira SL, Klein C, Grunewald A. Mitochondria and Parkinson’s disease: clinical, molecular, and translational aspects. J Parkinsons Dis. 2021;11(1):45–60. doi:10.3233/JPD-201981
   PubMedGoogle Scholar
• Illarioshkin SN, Klyushnikov SA, Vigont VA, Seliverstov YA, Kaznacheyeva EV. Molecular Pathogenesis in Huntington’s Disease. Biochemistry (Mosc). 2018;83(9):1030–1039. doi:10.1134/S0006297918090043
   PubMed Web of Science ®Google Scholar
• Zhuang L, Jia K, Chen C, et al. DYRK1B-STAT3 drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics. Circulation. 2022;145(11):829–846. doi:10.1161/CIRCULATIONAHA.121.055727
   PubMed Web of Science ®Google Scholar
• Rius-Perez S, Torres-Cuevas I, Millan I, Ortega AL, Perez S. PGC-1alpha, Inflammation, and Oxidative Stress: An Integrative View in Metabolism. Oxid Med Cell Longev. 2020;2020:1452696. doi:10.1155/2020/1452696
   PubMed Web of Science ®Google Scholar
• Jamwal S, Blackburn JK, Elsworth JD. PPARgamma/PGC1alpha signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacol Ther. 2021;219:107705. doi:10.1016/j.pharmthera.2020.107705
   PubMed Web of Science ®Google Scholar
• Yadav H, Quijano C, Kamaraju AK, et al. Protection from obesity and diabetes by blockade of TGF-beta/Smad3 signaling. Cell Metab. 2011;14(1):67–79. doi:10.1016/j.cmet.2011.04.013
   PubMed Web of Science ®Google Scholar
• Villena JA. New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond. FEBS J. 2015;282(4):647–672. doi:10.1111/febs.13175
   PubMed Web of Science ®Google Scholar
• Wu S, Zou MH. AMPK, Mitochondrial function, and cardiovascular disease. Int J Mol Sci. 2020;21(14):4987.
   PubMed Web of Science ®Google Scholar
• Tang BL. Sirt1 and the Mitochondria. Mol Cells. 2016;39(2):87–95.
   PubMed Web of Science ®Google Scholar
• Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458(7241):1056–1060. doi:10.1038/nature07813
   PubMed Web of Science ®Google Scholar
• El SS. Biochemical origin of the Warburg effect in light of 15 years of research experience: a novel evidence-based view (An Expert Opinion Article). Onco Targets Ther. 2023;16:143–155. doi:10.2147/OTT.S397593
   PubMed Web of Science ®Google Scholar
• Titov DV, Cracan V, Goodman RP, Peng J, Grabarek Z, Mootha VK. Complementation of mitochondrial electron transport chain by manipulation of the NAD + /NADH ratio. Science. 2016;352(6282):231–235. doi:10.1126/science.aad4017
   PubMed Web of Science ®Google Scholar
• Lee JJ, Ng SC, Hsu JY, et al. Galangin Reverses H(2)O(2)-Induced Dermal Fibroblast Senescence via SIRT1-PGC-1alpha/Nrf2 Signaling. Int J Mol Sci. 2022;23(3):1387.
   PubMed Web of Science ®Google Scholar
• Perez S, Rius-Perez S, Finamor I, et al. Obesity causes PGC-1alpha deficiency in the pancreas leading to marked IL-6 upregulation via NF-kappaB in acute pancreatitis. J Pathol. 2019;247(1):48–59. doi:10.1002/path.5166
   PubMed Web of Science ®Google Scholar
• Niel R, Le Moyec L, Launay T, et al. Physical performance level in sarcomeric mitochondria creatine kinase knockout mouse model throughout ageing. Exp Gerontol. 2021;146:111246. doi:10.1016/j.exger.2021.111246
   PubMed Web of Science ®Google Scholar
• Li Y, Feng YF, Liu XT, et al. Songorine promotes cardiac mitochondrial biogenesis via Nrf2 induction during sepsis. Redox Biol. 2021;38:101771. doi:10.1016/j.redox.2020.101771
   PubMed Web of Science ®Google Scholar
• Liu J, Du S, Kong Q, et al. HSPA12A attenuates lipopolysaccharide-induced liver injury through inhibiting caspase-11-mediated hepatocyte pyroptosis via PGC-1alpha-dependent acyloxyacyl hydrolase expression. Cell Death Differ. 2020;27(9):2651–2667. doi:10.1038/s41418-020-0536-x
   PubMed Web of Science ®Google Scholar
• Wang R, Li JJ, Diao S, et al. Metabolic stress modulates Alzheimer’s beta-secretase gene transcription via SIRT1-PPARgamma-PGC-1 in neurons. Cell Metab. 2013;17(5):685–694. doi:10.1016/j.cmet.2013.03.016
   PubMed Web of Science ®Google Scholar
• James MO, Yan Z, Cornett R, et al. Pharmacokinetics and metabolism of [14C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. Drug Metab Dispos. 1998;26(11):1134–1143.
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Toshima K, Watanabe T, et al. Effects of dichloroacetate on pyruvate metabolism in rat brain in vivo. Pediatr Res. 1984;18(10):936–938. doi:10.1203/00006450-198410000-00005
   PubMed Web of Science ®Google Scholar
• Lin EL, Mattox JK, Daniel FB. Tissue distribution, excretion, and urinary metabolites of dichloroacetic acid in the male Fischer 344 rat. J Toxicol Environ Health. 1993;38(1):19–32. doi:10.1080/15287399309531697
   PubMed Web of Science ®Google Scholar
• Shroads AL, Guo X, Dixit V, Liu HP, James MO, Stacpoole PW. Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity. J Pharmacol Exp Ther. 2008;324(3):1163–1171. doi:10.1124/jpet.107.134593
   PubMed Web of Science ®Google Scholar
• Saghir SA, Schultz IR. Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats. Environ Health Perspect. 2002;110(8):757–763. doi:10.1289/ehp.02110757
   PubMed Web of Science ®Google Scholar
• Lantum HB, Baggs RB, Krenitsky DM, Board PG, Anders MW. Immunohistochemical localization and activity of glutathione transferase zeta (GSTZ1-1) in rat tissues. Drug Metab Dispos. 2002;30(6):616–625. doi:10.1124/dmd.30.6.616
   PubMed Web of Science ®Google Scholar
• Squirewell EJ, Smeltz MG, Rowland-Faux L, Horne LP, Stacpoole PW, James MO. Effects of Multiple Doses of Dichloroacetate on GSTZ1 Expression and Activity in Liver and Extrahepatic Tissues of Young and Adult Rats. Drug Metab Dispos. 2020;48(11):1217–1223. doi:10.1124/dmd.120.000142
   PubMed Web of Science ®Google Scholar
• Wells PG, Moore GW, Rabin D, Wilkinson GR, Oates JA, Stacpoole PW. Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans. Diabetologia. 1980;19(2):109–113. doi:10.1007/BF00421855
   PubMed Web of Science ®Google Scholar
• Anderson WB, Board PG, Gargano B, Anders MW. Inactivation of glutathione transferase zeta by dichloroacetic acid and other fluorine-lacking alpha-haloalkanoic acids. Chem Res Toxicol. 1999;12(12):1144–1149. doi:10.1021/tx990085l
   PubMed Web of Science ®Google Scholar
• Li W, James MO, McKenzie SC, Calcutt NA, Liu C, Stacpoole PW. Mitochondrion as a novel site of dichloroacetate biotransformation by glutathione transferase zeta 1. J Pharmacol Exp Ther. 2011;336(1):87–94. doi:10.1124/jpet.110.173195
   PubMed Web of Science ®Google Scholar
• Smeltz MG, Hu Z, Zhong G, et al. Mitochondrial Glutathione Transferase Zeta 1 Is Inactivated More Rapidly by Dichloroacetate than the Cytosolic Enzyme in Adult and Juvenile Rat Liver. Chem Res Toxicol. 2019;32(10):2042–2052. doi:10.1021/acs.chemrestox.9b00207
   PubMed Web of Science ®Google Scholar
• Zhong G, James MO, Smeltz MG, et al. Age-Related Changes in Expression and Activity of Human Hepatic Mitochondrial Glutathione Transferase Zeta1. Drug Metab Dispos. 2018;46(8):1118–1128. doi:10.1124/dmd.118.081810
   PubMed Web of Science ®Google Scholar
• James MO, Stacpoole PW. Pharmacogenetic considerations with dichloroacetate dosing. Pharmacogenomics. 2016;17(7):743–753. doi:10.2217/pgs-2015-0012
   PubMed Web of Science ®Google Scholar
• Jahn SC, Rowland-Faux L, Stacpoole PW, James MO. Chloride concentrations in human hepatic cytosol and mitochondria are a function of age. Biochem Biophys Res Commun. 2015;459(3):463–468. doi:10.1016/j.bbrc.2015.02.128
   PubMed Web of Science ®Google Scholar
• Zhong G, Li W, Gu Y, Langaee T, Stacpoole PW, James MO. Chloride and other anions inhibit dichloroacetate-induced inactivation of human liver GSTZ1 in a haplotype-dependent manner. Chem Biol Interact. 2014;215:33–39. doi:10.1016/j.cbi.2014.02.015
   PubMed Web of Science ®Google Scholar
• Jahn SC, Gay LA, Weaver CJ, et al. Age-related changes in miRNA expression influence GSTZ1 and other drug metabolizing enzymes. Drug Metab Dispos. 2020;48(7):563–569. doi:10.1124/dmd.120.090639
   PubMed Web of Science ®Google Scholar
• Shroads AL, Coats BS, McDonough CW, Langaee T, Stacpoole PW. Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children. J Clin Pharmacol. 2015;55(1):50–55. doi:10.1002/jcph.371
   PubMed Web of Science ®Google Scholar
• Langaee T, Wagner R, Horne LP, et al. Personalized dosing of Dichloroacetate using GSTZ1 clinical genotyping assay. Genet Test Mol Biomarkers. 2018;22(4):266–269. doi:10.1089/gtmb.2017.0261
   PubMed Web of Science ®Google Scholar
• Langaee TY, Zhong G, Li W, et al. The influence of human GSTZ1 gene haplotype variations on GSTZ1 expression. Pharmacogenet Genomics. 2015;25(5):239–245. doi:10.1097/FPC.0000000000000129
   PubMed Web of Science ®Google Scholar
• Lantum HB, Board PG, Anders MW. Kinetics of the biotransformation of maleylacetone and chlorofluoroacetic acid by polymorphic variants of human glutathione transferase zeta (hGSTZ1-1). Chem Res Toxicol. 2002;15(7):957–963. doi:10.1021/tx010095y
   PubMed Web of Science ®Google Scholar
• Li W, Gu Y, James MO, et al. Prenatal and postnatal expression of glutathione transferase zeta 1 in human liver and the roles of haplotype and subject age in determining activity with dichloroacetate. Drug Metab Dispos. 2012;40(2):232–239. doi:10.1124/dmd.111.041533
   PubMed Web of Science ®Google Scholar
• Shroads AL, Langaee T, Coats BS, et al. Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. J Clin Pharmacol. 2012;52(6):837–849. doi:10.1177/0091270011405664
   PubMed Web of Science ®Google Scholar
• Jiang Y, Milavetz G, James MO, An G. A mechanism-based pharmacokinetic enzyme turnover model for dichloroacetic acid autoinhibition in rats. J Pharm Sci. 2017;106(5):1396–1404. doi:10.1016/j.xphs.2017.01.032
   PubMed Web of Science ®Google Scholar
• Wehmas LC, DeAngelo AB, Hester SD, et al. Metabolic disruption early in life is associated with latent carcinogenic activity of dichloroacetic acid in mice. Toxicol Sci. 2017;159(2):354–365. doi:10.1093/toxsci/kfx146
   PubMed Web of Science ®Google Scholar
• Wood CE, Hester SD, Chorley BN, et al. Latent carcinogenicity of early-life exposure to dichloroacetic acid in mice. Carcinogenesis. 2015;36(7):782–791. doi:10.1093/carcin/bgv057
   PubMed Web of Science ®Google Scholar
• Program NT Report on carcinogens monograph on haloacetic acids found as water disinfection by-products: RoC monograph 12. Research Triangle Park (NC): National Toxicology Program; 2018.
   Google Scholar
• Abdelmalak M, Lew A, Ramezani R, et al. Long-term safety of dichloroacetate in congenital lactic acidosis. Mol Genet Metab. 2013;109(2):139–143. doi:10.1016/j.ymgme.2013.03.019
   PubMed Web of Science ®Google Scholar
• Stacpoole PW, Harwood HJ, Cameron DF, et al. Chronic toxicity of dichloroacetate: possible relation to thiamine deficiency in rats. Fundam Appl Toxicol. 1990;14(2):327–337. doi:10.1016/0272-0590(90)90212-3
   PubMedGoogle Scholar
• Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev. 1998;30(3):499–539. doi:10.3109/03602539808996323
   PubMed Web of Science ®Google Scholar
• Board PG, Anders MW. Human glutathione transferase zeta. Methods Enzymol. 2005;401:61–77.
   PubMed Web of Science ®Google Scholar
• St-Louis M, Tanguay RM. Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview. Hum Mutat. 1997;9(4):291–299. doi:10.1002/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Lantum HB, Cornejo J, Pierce RH, Anders MW. Perturbation of maleylacetoacetic acid metabolism in rats with dichloroacetic Acid-induced glutathione transferase zeta deficiency. Toxicol Sci. 2003;74(1):192–202. doi:10.1093/toxsci/kfg104
   PubMed Web of Science ®Google Scholar
• Andrade V, Mateus ML, Batoreu MC, Aschner M, Dos SA. Urinary delta-ALA: a potential biomarker of exposure and neurotoxic effect in rats co-treated with a mixture of lead, arsenic and manganese. Neurotoxicology. 2013;38:33–41. doi:10.1016/j.neuro.2013.06.003
   PubMed Web of Science ®Google Scholar
• Morrow G, Tanguay RM. Biochemical and clinical aspects of hereditary tyrosinemia type 1. Adv Exp Med Biol. 2017;959:9–21.
   PubMed Web of Science ®Google Scholar
• Baker PR, Cramer SD, Kennedy M, Assimos DG, Holmes RP. Glycolate and glyoxylate metabolism in HepG2 cells. Am J Physiol Cell Physiol. 2004;287(5):C1359–C1365. doi:10.1152/ajpcell.00238.2004
   PubMed Web of Science ®Google Scholar
• Salido E, Pey AL, Rodriguez R, Lorenzo V. Primary hyperoxalurias: disorders of glyoxylate detoxification. Biochim Biophys Acta. 2012;1822(9):1453–1464. doi:10.1016/j.bbadis.2012.03.004
   PubMed Web of Science ®Google Scholar
• Sidhu H, Gupta R, Thind SK, Nath R. Oxalate metabolism in thiamine-deficient rats. Ann Nutr Metab. 1987;31(6):354–361. doi:10.1159/000177294
   PubMed Web of Science ®Google Scholar
• Berini SE, Tracy JA, Engelstad JK, Lorenz EC, Milliner DS, Dyck PJ. Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria. Muscle Nerve. 2015;51(3):449–454. doi:10.1002/mus.24495
   PubMed Web of Science ®Google Scholar
• Evans OB, Stacpoole PW. Prolonged hypolactatemia and increased total pyruvate dehydrogenase activity by dichloroacetate. Biochem Pharmacol. 1982;31(7):1295–1300. doi:10.1016/0006-2952(82)90019-3
   PubMed Web of Science ®Google Scholar
• Kurlemann G, Paetzke I, Moller H, et al. Therapy of complex I deficiency: peripheral neuropathy during dichloroacetate therapy. Eur J Pediatr. 1995;154(11):928–932. doi:10.1007/BF01957508
   PubMed Web of Science ®Google Scholar
• El-Hattab AW, Zarante AM, Almannai M, Scaglia F. Therapies for mitochondrial diseases and current clinical trials. Mol Genet Metab. 2017;122(3):1–9. doi:10.1016/j.ymgme.2017.09.009
   PubMed Web of Science ®Google Scholar
• Broxton CN, Kaur P, Lavorato M, et al. Dichloroacetate and thiamine improve survival and mitochondrial stress in a C. elegans model of dihydrolipoamide dehydrogenase deficiency. JCI Insight. 2022;7(20). doi:10.1172/jci.insight.156222
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006;66(3):324–330. doi:10.1212/01.wnl.0000196641.05913.27
   PubMed Web of Science ®Google Scholar
• Garon EB, Christofk HR, Hosmer W, et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2014;140(3):443–452. doi:10.1007/s00432-014-1583-9
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2(31):31ra34. doi:10.1126/scitranslmed.3000677
   PubMed Web of Science ®Google Scholar
• Dunbar EM, Coats BS, Shroads AL, et al. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs. 2014;32(3):452–464. doi:10.1007/s10637-013-0047-4
   PubMed Web of Science ®Google Scholar
• Chu QS, Sangha R, Spratlin J, et al. A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors. Invest New Drugs. 2015;33(3):603–610. doi:10.1007/s10637-015-0221-y
   PubMed Web of Science ®Google Scholar
• Stacpoole PW, Gilbert LR, Neiberger RE, et al. Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics. 2008;121(5):e1223–e1228. doi:10.1542/peds.2007-2062
   PubMed Web of Science ®Google Scholar
• Tian DD, Bennett SK, Coupland LA, et al. GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial. Pharmacol Res Perspect. 2019;7(6):e526. doi:10.1002/prp2.526
   Web of Science ®Google Scholar
• Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics. 2006;117(5):1519–1531. doi:10.1542/peds.2005-1226
   PubMed Web of Science ®Google Scholar
• Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183–3195. doi:10.7150/thno.52570
   PubMed Web of Science ®Google Scholar
• Wong KH, Riaz MK, Xie Y, et al. Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier. Int J Mol Sci. 2019;20(2):381. doi:10.3390/ijms20020381
   PubMed Web of Science ®Google Scholar
• Verma R, Kaushik A, Almeer R, Rahman MH, Abdel-Daim MM, Kaushik D. Improved Pharmacodynamic Potential of Rosuvastatin by Self-Nanoemulsifying Drug Delivery System: an in vitro and in vivo Evaluation. Int J Nanomedicine. 2021;16:905–924. doi:10.2147/IJN.S287665
   PubMed Web of Science ®Google Scholar
• Verma R, Mittal V, Pandey P, et al. Exploring the role of self-nanoemulsifying systems in drug delivery: challenges, issues, applications and recent advances. Curr Drug Deliv. 2023;20(9):1241–1261. doi:10.2174/1567201819666220519125003
   PubMed Web of Science ®Google Scholar
• Verma R, Kaushik D. In vitro Lipolysis as a Tool for the Establishment of IVIVC for Lipid-Based Drug Delivery Systems. Curr Drug Deliv. 2019;16(8):688–697. doi:10.2174/1567201816666190620115716
   PubMed Web of Science ®Google Scholar
• Liang Y, Iqbal Z, Lu J, et al. Cell-derived nanovesicle-mediated drug delivery to the brain: Principles and strategies for vesicle engineering. Mol Ther. 2023;31(5):1207–1224. doi:10.1016/j.ymthe.2022.10.008
   PubMed Web of Science ®Google Scholar
• Pracharova J, Novohradsky V, Kostrhunova H, et al. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells. Dalton Trans. 2018;47(35):12197–12208. doi:10.1039/C8DT02236D
   PubMed Web of Science ®Google Scholar
• Starha P, Travnicek Z, Vanco J, Dvorak Z. Half-Sandwich Ru(II) and Os(II) Bathophenanthroline Complexes Containing a Releasable Dichloroacetato Ligand. Molecules. 2018;23(2):420. doi:10.3390/molecules23020420
   PubMed Web of Science ®Google Scholar
• Abanades LI, Haddad S, Rodrigo-Munoz JM, et al. Mechanistic Investigation into the Selective Anticancer Cytotoxicity and Immune System Response of Surface-Functionalized, Dichloroacetate-Loaded, UiO-66 Nanoparticles. ACS Appl Mater Interfaces. 2018;10(6):5255–5268. doi:10.1021/acsami.7b17756
   PubMed Web of Science ®Google Scholar
• Abanades LI, Haddad S, Rodrigo-Munoz JM, et al. Surface-Functionalization of Zr-Fumarate MOF for Selective Cytotoxicity and Immune System Compatibility in Nanoscale Drug Delivery. ACS Appl Mater Interfaces. 2018;10(37):31146–31157. doi:10.1021/acsami.8b11652
   PubMed Web of Science ®Google Scholar
• Yang J, Cao Q, Zhang H, et al. Targeted reversal and phosphorescence lifetime imaging of cancer cell metabolism via a theranostic rhenium(I)-DCA conjugate. Biomaterials. 2018;176:94–105. doi:10.1016/j.biomaterials.2018.05.040
   PubMed Web of Science ®Google Scholar
• Lázaro AI, Abanades LS, Forgan RS. Enhancing anticancer cytotoxicity through bimodal drug delivery from ultrasmall Zr MOF nanoparticles. Chem Commun (Camb). 2018;54(22):2792–2795. doi:10.1039/C7CC09739E
   PubMed Web of Science ®Google Scholar
• Choi H, Choi Y, Yim HY, Mirzaaghasi A, Yoo JK, Choi C. Biodistribution of Exosomes and Engineering Strategies for Targeted Delivery of Therapeutic Exosomes. Tissue Eng Regen Med. 2021;18(4):499–511. doi:10.1007/s13770-021-00361-0
   PubMed Web of Science ®Google Scholar
• Meng W, He C, Hao Y, Wang L, Li L, Zhu G. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Deliv. 2020;27(1):585–598. doi:10.1080/10717544.2020.1748758
   PubMed Web of Science ®Google Scholar
• Do AD, Kurniawati I, Hsieh CL, Wong TT, Lin YL, Sung SY. Application of Mesenchymal Stem Cells in Targeted Delivery to the Brain: Potential and Challenges of the Extracellular Vesicle-Based Approach for Brain Tumor Treatment. Int J Mol Sci. 2021;22(20):11187. doi:10.3390/ijms222011187
   PubMed Web of Science ®Google Scholar
• Luo Y, Yang H, Zhou YF, Hu B. Dual and multi-targeted nanoparticles for site-specific brain drug delivery. J Control Release. 2020;317:195–215. doi:10.1016/j.jconrel.2019.11.037
   PubMed Web of Science ®Google Scholar
• Hu B, Dai F, Fan Z, Ma G, Tang Q, Zhang X. Nanotheranostics: Congo Red/Rutin-MNPs with Enhanced Magnetic Resonance Imaging and H2O2-Responsive Therapy of Alzheimer’s Disease in APPswe/PS1dE9 Transgenic Mice. Adv Mater. 2015;27(37):5499–5505. doi:10.1002/adma.201502227
   PubMed Web of Science ®Google Scholar
• Qiao C, Yang J, Shen Q, et al. Traceable Nanoparticles with Dual Targeting and ROS Response for RNAi-Based Immunochemotherapy of Intracranial Glioblastoma Treatment. Adv Mater. 2018;30(18):e1705054. doi:10.1002/adma.201705054
   PubMed Web of Science ®Google Scholar
• Goyal K, Konar A, Kumar B, Koul V. Lactoferrin-conjugated pH and redox-sensitive polymersomes based on PEG-S-S-PLA-PCL-OH boost delivery of bacosides to the brain. Nanoscale. 2018;10(37):17781–17798. doi:10.1039/C8NR03828G
   PubMed Web of Science ®Google Scholar
• Itoh Y, Esaki T, Shimoji K, et al. Dichloroacetate effects on glucose and lactate oxidation by neurons and astroglia in vitro and on glucose utilization by brain in vivo. Proc Natl Acad Sci U S A. 2003;100(8):4879–4884. doi:10.1073/pnas.0831078100
   PubMed Web of Science ®Google Scholar